Association of cardiotrophin-like cytokine factor 1 levels in peripheral blood mononuclear cells with bone mineral density and osteoporosis in postmenopausal women

Abstract

Background Recent research has suggested that cardiotrophin-like cytokine factor 1 (CLCF1) may be an important regulator of bone homeostasis. Furthermore, a whole gene chip analysis suggested that the expression levels of CLCF1 in the peripheral blood mononuclear cells (PBMCs) were downregulated in postmenopausal women with osteoporosis. This study aimed to assess whether the expression levels of CLCF1 in PBMCs can reflect the severity of bone mass loss and the related fracture risk. Methods In all, 360 postmenopausal women, aged 50 to 80\u2009years, were included in the study. A survey to evaluate the participants’ health status, measurement of bone mineral density (BMD), routine blood test, and CLCF1 expression level test were performed. Results Based on the participants’ bone health, 27 (7.5%), 165 (45.83%), and 168 (46.67%) participants were divided into the normal, osteopenia, and osteoporosis groups, respectively. CLCF1 protein levels in the normal and osteopenia groups were higher than those in the osteoporosis group. While the CLCF1 mRNA level was positively associated with the BMD of total femur ( r = 0.169, p = 0.011) and lumbar spine ( r = 0.176, p = 0.001), the protein level was positively associated with the BMD of the lumbar spine ( r = 0.261, p <\u20090.001), femoral neck ( r = 0.236, p = 0.001), greater trochanter ( r = 0.228, p = 0.001), and Ward’s triangle ( r = 0.149, p = 0.036). Both the mRNA and protein levels were negatively associated with osteoporosis development ( r = −\u20090.085, p = 0.011 and r = −\u20090.173, p = 0.014, respectively). The association between CLCF1 protein level and fracture risk was not significant after adjusting for BMD. Conclusions To our knowledge, this is the first clinical study to show that CLCF1 expression levels in the PBMCs of postmenopausal women can reflect the amount of bone mass or the severity of bone mass loss.